Thursday, April 19, 2007
April 19th, 2007 - message from New York reported event Friday April 20th - 10-12:30 pm Central Park at West 67th St, NY
I'm a reporter at New York Magazine, and we're organizing a big photo shoot
in Central Park TOMORROW.
I'm hoping that you could post it on your blog, and maybe even attend the
shoot yourself, if you live in the NY area! We're really working hard to
find just another 40 people to
come, and time is running out!
All the best,
212 508 0668
New York Magazine Cover Shoot
New York Magazine is currently working on a very important feature story
about New Yorkers living with cancer. For a potential cover, we would like
to gather 300-350 New Yorkers living with cancer or in remission, in one
place, for an incredibly positive & moving picture. We are looking for
people of all ages, and of all races to to be photographed together.
We want to show the unity of the fight, so we are asking everyone to dress
on their own, as they normally would- no organization specific t-shirts. We
want the picture to look like a beautiful group of wildflowers. We hope this
will help raise awareness & funding for all.
Any interested participants should contact me directly at
Logistical info below:
FINAL CALL SHEET/NEW YORKERS LIVING WITH CANCER
Date: Friday April 20th, 2007
Check-In Location: Tavern on the Green, Central Park at West
New York Magazine contacts: Katie Charles 202.368.1836; Alex Pollack
**IMPORTANT: Please arrive on time, as we have a very narrow window for the
permit from the Parks Department.
Let¹s try to have some color even though spring is late. Please dress in the
brightest color coat that you have- we don¹t want everyone in black or navy
coats, or the picture will look dreary. Please bring minimal bags/stuff with
you so we don¹t add unnecessary clutter to the photo. You will be asked to
fill out the attached 2 page form at the check-in table at Tavern on the
Green. To expedite the check-in process, if you are able to fill out the
form, print it & bring it with you, it would be very helpful. We will be
making individual portraits of each of you prior to the group shot.
IN CASE OF RAIN:
We have set up a rain date, should the weather not cooperate on Thursday
night/Friday. We have also set up a rain hotline. For updated information on
Friday morning, please call 212.508.0551.
Rain Date: Sunday April 22, 2007
Location: Pier 59 Studios, 59 Chelsea Piers
(btwn. 17th & 18th Streets on the water), Studio C
We¹re very excited to meet you all and to collaborate on this beautiful and
Katie Charles and Alex Pollack
Wednesday, April 18, 2007
Patient Navigation in Cancer Care--Program Search: "This site is not intended for use by patients."
Friday, April 13, 2007
Monday, April 09, 2007
Wednesday, April 04, 2007
April 2007: Gynecologic Oncology : A cost–effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian
Second-line chemotherapy is cost-effective for patients with platinum-sensitive recurrent EOC. Due to minimal improvements in overall survival, third- and fourth-line chemotherapy are not cost-effective strategies.
ScienceDirect - Gynecologic Oncology : A cost–effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer
Tuesday, April 03, 2007
2007 Journal of Emergency Nursing : Influence of Time-to-Interventions for Emergency Department Critical Care Patients on Hospital Mortality
ScienceDirect - Journal of Emergency Nursing : Influence of Time-to-Interventions for Emergency Department Critical Care Patients on Hospital Mortality
Saturday, March 31, 2007
Canada - Best Practice & Research Clinical Obstetrics & Gynaecology : Patient safety in women's health-care: professional colleges can make a differe
ScienceDirect - Best Practice & Research Clinical Obstetrics & Gynaecology : Patient safety in women's health-care: professional colleges can make a difference. The Society of Obstetricians and Gynaecologists of Canada MOREOB program
Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy? -- Silber et al. 25 (10): 1169 -- Journal of Clinical Oncol
Does Ovarian Cancer Treatment and Survival Differ by the Specialty Providing Chemotherapy? -- Silber et al. 25 (10): 1169 -- Journal of Clinical Oncology
Sunday, March 25, 2007
OVARIAN CANCER and US: Ovarian Cancer - What You Need to Know - 6/13 of the women portrayed 'In Your Own Words' have since died (since publication in
OVARIAN CANCER and US: Ovarian Cancer - What You Need to Know - 6/13 of the women portrayed 'In Your Own Words' have since died (since publication in 2005)
Saturday, March 24, 2007
Gynecologic Oncology : A cost–effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian
ScienceDirect - Gynecologic Oncology : A cost–effectiveness analysis of chemotherapy for patients with recurrent platinum-sensitive epithelial ovarian cancer:
Second-line chemotherapy is cost-effective for patients with platinum-sensitive recurrent EOC. Due to minimal improvements in overall survival, third- and fourth-line chemotherapy are not cost-effective strategies."
JAMA -- Abstract: Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome: A Systematic Review
JAMA -- Abstract: Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome: A Systematic Review, September 27, 2006, Lindor et al. 296 (12): 1507
Recommendations for the Care of Individuals With an Inherited Predisposition to Lynch Syndrome
A Systematic Review
Context About 2% of all colorectal cancer occurs in the context of the autosomal dominantly inherited Lynch syndrome, which is due to mutations in mismatch repair genes. Potential risk-reducing interventions are recommended for individuals known to have these mutations.
Objectives To review cancer risks and data on screening efficacy in the context of Lynch syndrome (hereditary nonpolyposis colorectal cancer) and to provide recommendations for clinical management for affected families, based on available evidence and expert opinion.
Data Sources and Study Selection A systematic literature search using PubMed and the Cochrane Database of Systematic Reviews, reference list review of retrieved articles, manual searches of relevant articles, and direct communication with other researchers in the field. Search terms included hereditary non-polyposis colon cancer, Lynch syndrome, microsatellite instability, mismatch repair genes, and terms related to the biology of Lynch syndrome. Only peer-reviewed, full-text, English-language articles concerning human subjects published between January 1, 1996, and February 2006 were included. The US Preventive Services Task Force's 2-tier system was adapted to describe the quality of evidence and to assign strength to the recommendations for each guideline.
Evidence Synthesis The evidence supports colonoscopic surveillance for individuals with Lynch syndrome, although the optimal age at initiation and frequency of examinations is unresolved. Colonoscopy is recommended every 1 to 2 years starting at ages 20 to 25 years (age 30 years for those with MSH6 mutations), or 10 years younger than the youngest age of the person diagnosed in the family. While fully acknowledging absence of demonstrated efficacy, the following are also recommended annually: endometrial sampling and transvaginal ultrasound of the uterus and ovaries (ages 30-35 years); urinalysis with cytology (ages 25-35 years); history, examination, review of systems, education and genetic counseling regarding Lynch syndrome (age 21 years). Regular colonoscopy was favored for at-risk persons without colorectal neoplasia. For individuals who will undergo surgical resection of a colon cancer, subtotal colectomy is favored. Evidence supports the efficacy of prophylactic hysterectomy and oophorectomy.
Conclusions The past 10 years have seen major advances in the understanding of Lynch syndrome. Current recommendations regarding cancer screening and prevention require careful consultation between clinicians, clinical cancer genetic services, and well-informed patients.
Author Affiliations: Departments of Medical Genetics (Drs Lindor and Petersen) and Health Sciences Research (Dr Petersen), Mayo Clinic College of Medicine, Rochester, Minn; Social and Behavioral Research Branch, National Human Genome Research Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, Md (Mr Hadley); Department of Medicine and Huntsman Cancer Institute, University of Utah, and Veterans Affairs Medical Center, Salt Lake City (Dr Kinney); Medical Oncology, Maine Center for Cancer Medicine and Blood Disorders and Maine Medical Center, Portland (Dr Miesfeldt); Departments of Gynecologic Oncology (Dr Lu) and Gastrointestinal Medicine and Nutrition (Dr Lynch), M. D. Anderson Cancer Center, University of Texas, Houston; Department of Medical History and Ethics, University of Washington, Seattle (Dr Burke); and Schools of Nursing and Medicine, Oregon Health and Science University, Portland (Dr Press).
This Week in JAMA
Prediction of MLH1 and MSH2 Mutations in Lynch Syndrome
Judith Balmaña, David H. Stockwell, Ewout W. Steyerberg, Elena M. Stoffel, Amie M. Deffenbaugh, Julia E. Reid, Brian Ward, Thomas Scholl, Brant Hendrickson, John Tazelaar, Lynn Anne Burbidge, and Sapna Syngal
Prediction of Germline Mutations and Cancer Risk in the Lynch Syndrome
Sining Chen, Wenyi Wang, Shing Lee, Khedoudja Nafa, Johanna Lee, Kathy Romans, Patrice Watson, Stephen B. Gruber, David Euhus, Kenneth W. Kinzler, Jeremy Jass, Steven Gallinger, Noralane M. Lindor, Graham Casey, Nathan Ellis, Francis M. Giardiello, Kenneth Offit, Giovanni Parmigiani, and for the Colon Cancer Family Registry